AXDX - mmillionaire - spoke with management everything is still in progress and on target for early Q2 2016 for monetization of the diagnostic technology... additional interest from CDC and other entities related to the diagnostic technology as it pertains to MRSA's and other infections give the technology most testing data and additionally publication materials and exposures to infectious disease physicians, pathologists and molecular laboratory directors...
The patterns of large run ups and retreats is astounding... this is the result of being a development stage company with limited revenues and a moderately long horizon for diagnostic technology to reach marketability...
This accelerated diagnostic tool is a "razor and razor blade product model"... device may sale for $50K... the specimen cartridges may sale for $150... every hospital with an ICU, CCU and Surgical center will likely buy the device for better patient outcomes for hospital related infections which are one of the highest mortalities in US hospitals... and obviously large cost due to lawsuits... so every Hospital Board (risk management) will want to spend the cost to have this accelerated diagnostic tool in their facilities...
Another important factor to monitor in 2014... AXDX was added to Russell 2000 index in June 2013 and subsequently market value exceeded $1B and was removed as of June 2014... it is highly likely that as of June 2014 AXDX will still be under $1B market value... and will be re-added to Russell 2000 index... this creates demand for shares as the Russell 2000 index through funds that access this index account for Trillions of dollars of assets...
As you see AXDX is in retreat... which is consistent with prior pattern actions... I start tracking closely in the 16s... I start buying in the 15s... it could go lower if the general market conditions go south... regardless... it has popped to over 30s twice in 2014... this stock loves Octobers... look at patterns over past three years...
This is a nice stock to buy low and sale high... and repeat... I gain lots of comfort from the fact that once the accelerated diagnostic tool achieves marketability... the North American Market for this product is over $1B for the device... more for the ongoing specimen cartridges annuity stream... the International Market for this product is over $1.5B... that is a healthy market to start selling to...
I believe the target PPS for 2nd Quarter 2016 might be conservatively $40 to $60 PPS... so this is a great LONG buy and HOLD stock as well...
Great management team that has been successful repeatedly in this sector with other companies such as Ventana and Stericycle... do some diligence and take a chance...
GOOD LUCK TO ALL IN 2015!!!
News 
Market Data 
Discover 
